Therefore, we focused on validating the anti-TROVE2 and anti-PCNA autoantibodies in CSF specimens of SLE patients, with RPLP0, RPLP1, and RPLP2 as positive controls. This evidence concerns the gene RPLP2 and systemic lupus erythematosus.